Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04579380 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT04579380 · ClinicalTrials.gov record · last posted 2026-08-21

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Name: Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations — clinical trial record (NCT04579380)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 2

SponsorSeagen, a wholly owned subsidiary of Pfizer

Started2021-01-11

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This trial studies how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The solid tumors studied in this trial have either spread to other parts of the body (metastatic) or cannot be removed completely with surgery (unresectable). All participants will get both tucatinib and trastuzumab. People with hormone-receptor positive breast cancer will also get a drug called fulvestrant. The trial will also look at what side effects happen. A side effect is anything a drug does besides treating cancer.

Protocol amendment history 1 change detected by DataLookout

2026-08-22

Completion pushed: 2026-04-30 → 2026-12-31

Trial Details

NCT Number	NCT04579380
Lead Sponsor	Seagen, a wholly owned subsidiary of Pfizer
Conditions	Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
Enrollment	217 participants
Start Date	2021-01-11
Primary Completion	2023-11-01 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-21